We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Waters (WAT) to Report Q1 Earnings: What's in the Offing?
Read MoreHide Full Article
Waters Corporation (WAT - Free Report) is scheduled to report first-quarter 2020 results on Apr 28.
For first-quarter 2020, Waters expects non-GAAP earnings between $1.55 and $1.65 per share. The Zacks Consensus Estimate for earnings is pegged at $1.42 per share, suggesting a decline of 11.25% from the year-ago quarter.
The company anticipates net sales growth between 0% and 2% on a constant currency basis. The Zacks Consensus Estimate for sales currently stands at $485.87 million, indicating a decline of 5.45% from the prior-year quarter.
The company has beat estimates twice, while missing once and matching the other. It has a trailing dour-quarter negative earnings surprise of 0.03%, on average.
Waters’ new technologies are likely to have aided its momentum across pharmaceutical and biomedical research categories. These, in turn, are expected to have driven sales in the governmental and academic market during the first quarter.
Further, the company’s strong investments in liquid chromatography instruments, mass spectrometers and chemistries, and new product introductions are likely to have contributed to the company’s performance in the large molecule market during the quarter to be reported.
Moreover, new products like BioAccord, Cyclic IMS, SYNAPT XS and two new tandem quad mass spectrometers are expected to have benefited the performance of Waters segment in the to-be-reported quarter.
Additionally, strong instruments and product portfolio is likely to have aided the performance of TA segment during the first quarter.
Despite weakness in the materials characterization, strength in food testing is anticipated to have aided the company’s performance in the industrial market during the quarter under review.
Further, solid momentum across academic and pharmaceutical customers owing to robust mass spectrometers instruments is likely to have driven Waters’ performance in Europe in the to-be-reported quarter.
Further, continuous recovery in the Indian pharmaceutical market is expected to have aided the company during the first quarter.
Further, strength in food testing and solid momentum across large molecule market and biomedical research applications are expected to have contributed to sales in the U.S. market in the to-be-reported quarter.
However, sluggishness in the small molecule pharmaceutical market, material science and clinical applications are likely to have acted as headwinds in the United States.
Slowdown in the capital spending in the small molecule market is expected to have weighed on the company’s first-quarter performance.
Additionally, softness in China owing to government policy changes and the coronavirus outbreak is likely to get reflected in Waters’ first-quarter results.
Moreover, the full blown economic crisis induced by the rapidly spreading coronavirus is expected to have dampened the capital purchasing by customers across the key market during the quarter under review. This is expected to have remained a major headwind.
What Our Model Says
Our proven model does not conclusively predicts an earnings beat for Waters this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Waters has an Earnings ESP of -4.89% and a Zacks Rank #3.
Stocks to Consider
Here are some stocks you may consider, as our proven model shows that these have the right combination of elements to post an earnings beat this quarter.
Baidu, Inc. (BIDU - Free Report) has an Earnings ESP of +10.09% and a Zacks Rank of 2.
Etsy, Inc. (ETSY - Free Report) has an Earnings ESP of +8.17% and a Zacks Rank #2.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Waters (WAT) to Report Q1 Earnings: What's in the Offing?
Waters Corporation (WAT - Free Report) is scheduled to report first-quarter 2020 results on Apr 28.
For first-quarter 2020, Waters expects non-GAAP earnings between $1.55 and $1.65 per share. The Zacks Consensus Estimate for earnings is pegged at $1.42 per share, suggesting a decline of 11.25% from the year-ago quarter.
The company anticipates net sales growth between 0% and 2% on a constant currency basis. The Zacks Consensus Estimate for sales currently stands at $485.87 million, indicating a decline of 5.45% from the prior-year quarter.
The company has beat estimates twice, while missing once and matching the other. It has a trailing dour-quarter negative earnings surprise of 0.03%, on average.
Waters Corporation Price and EPS Surprise
Waters Corporation price-eps-surprise | Waters Corporation Quote
Factors to Consider
Waters’ new technologies are likely to have aided its momentum across pharmaceutical and biomedical research categories. These, in turn, are expected to have driven sales in the governmental and academic market during the first quarter.
Further, the company’s strong investments in liquid chromatography instruments, mass spectrometers and chemistries, and new product introductions are likely to have contributed to the company’s performance in the large molecule market during the quarter to be reported.
Moreover, new products like BioAccord, Cyclic IMS, SYNAPT XS and two new tandem quad mass spectrometers are expected to have benefited the performance of Waters segment in the to-be-reported quarter.
Additionally, strong instruments and product portfolio is likely to have aided the performance of TA segment during the first quarter.
Despite weakness in the materials characterization, strength in food testing is anticipated to have aided the company’s performance in the industrial market during the quarter under review.
Further, solid momentum across academic and pharmaceutical customers owing to robust mass spectrometers instruments is likely to have driven Waters’ performance in Europe in the to-be-reported quarter.
Further, continuous recovery in the Indian pharmaceutical market is expected to have aided the company during the first quarter.
Further, strength in food testing and solid momentum across large molecule market and biomedical research applications are expected to have contributed to sales in the U.S. market in the to-be-reported quarter.
However, sluggishness in the small molecule pharmaceutical market, material science and clinical applications are likely to have acted as headwinds in the United States.
Slowdown in the capital spending in the small molecule market is expected to have weighed on the company’s first-quarter performance.
Additionally, softness in China owing to government policy changes and the coronavirus outbreak is likely to get reflected in Waters’ first-quarter results.
Moreover, the full blown economic crisis induced by the rapidly spreading coronavirus is expected to have dampened the capital purchasing by customers across the key market during the quarter under review. This is expected to have remained a major headwind.
What Our Model Says
Our proven model does not conclusively predicts an earnings beat for Waters this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Waters has an Earnings ESP of -4.89% and a Zacks Rank #3.
Stocks to Consider
Here are some stocks you may consider, as our proven model shows that these have the right combination of elements to post an earnings beat this quarter.
Pixelworks, Inc. (PXLW - Free Report) has an Earnings ESP of +5.26% and a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Baidu, Inc. (BIDU - Free Report) has an Earnings ESP of +10.09% and a Zacks Rank of 2.
Etsy, Inc. (ETSY - Free Report) has an Earnings ESP of +8.17% and a Zacks Rank #2.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>